Previously, we reported that GH-RH acts as a prostatic growth factor in experimental BPH and in autoimmune prostatitis models and its blockade with GH-RH antagonists offers therapeutic approaches for these conditions. This evidence concerns the gene GHRH and benign prostatic hyperplasia.